Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 7/2016

01-07-2016 | Guidelines/Clinical Trials/Meta-Analysis (J Kostis, Section Editor)

Renal Denervation: a Field in Flux

Authors: Luke J. Laffin, George L. Bakris

Published in: Current Hypertension Reports | Issue 7/2016

Login to get access

Abstract

SYMPLICITY HTN-3 was a pivotal moment for renal denervation as a treatment option for resistant hypertension. Prior unblinded studies were called into question given the negative results of the first sham-controlled trial of renal denervation. Reevaluation of the renal denervation procedure demonstrated that a more precise approach was needed to adequately denervate the kidney. This new approach has been implemented in two ongoing clinical trials, one on and one off medications to assess the new procedure’s efficacy and safety. These and other ongoing trials will be discussed in the context of older studies in this field. We focus on novel findings published following the release of SYMPLICITY HTN-3 data in early 2014 and look to the future of renal denervation in the treatment of primary hypertension.
Literature
1.•
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. Only major sham-controlled trial of renal denervation. It did not demonstrate any difference between renal denervation and sham procedure with respect to office blood pressure.CrossRefPubMed
2.
Papademetriou V, Tsioufis C, Doumas M. Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115(2):211–4.CrossRefPubMed
3.
Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593–8.CrossRefPubMed
4.
Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.CrossRef
5.
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.CrossRefPubMed
6.
Group SR, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef
7.
8.
Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015;21:20–4.CrossRefPubMed
9.
Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071–8.CrossRefPubMed
10.••
Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21. 12-month ambulatory and office blood pressure results from SYMPLICITY HTN-3. Data support no further reduction in office or ambulatory BP after 1-year of follow-up.CrossRefPubMed
11.
Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.CrossRefPubMed
12.
Schmid A, Schmieder R, Lell M, Janka R, Veelken R, Schmieder RE, et al. Mid-term vascular safety of renal denervation assessed by follow-up MR imaging. Cardiovasc Intervent Radiol. 2016;39(3):426–32.CrossRefPubMed
13.
Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635–43.CrossRefPubMed
14.
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.CrossRefPubMed
15.••
Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75. Preclinical porcine model of renal denervation established following negative results of SYMPLICITY HTN-3 that characterizes the types of ablations needed to maximally decrease norepinephrine levels and renal vasculature axon density.CrossRefPubMed
16.
Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.CrossRefPubMed
17.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68.CrossRefPubMedPubMedCentral
18.
Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 Study. Hypertension. 2015;65(2):407–13.CrossRefPubMed
19.
Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 Study. Hypertension. 2016;67(2):397–403.PubMed
20.
Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65.CrossRefPubMed
21.••
Sun D, Li C, Li M, Liu J, Wen S. Renal denervation vs pharmacotherapy for resistant hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2015. doi:10.​1111/​jch.​12742. Meta-analysis of 9 renal denervation versus pharmacotherapy trials in resistant hypertension, of which 6 were randomized. When only accounting for 6 randomized trials there was no difference in blood pressure lowering with renal denervation versus pharmacotherapy.
22.•
Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4):766–74. First published data from a prospective registry created to document the long-term safety and effectiveness of renal denervation in a real world patient population with hypertension. It also aims to gather data for other diseases characterized by elevated sympathetic drive.CrossRefPubMed
23.
Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33.CrossRefPubMed
24.
Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29(4):213–8.CrossRefPubMed
25.
Ricke J, Seidensticker M, Becker S, Schiefer J, Adamchic I, Lohfink K, et al. Renal sympathetic denervation by CT-guided ethanol injection: a phase II pilot trial of a novel technique. Cardiovasc Intervent Radiol. 2016;39(2):251–60.CrossRefPubMed
Metadata
Title
Renal Denervation: a Field in Flux
Authors
Luke J. Laffin
George L. Bakris
Publication date
01-07-2016
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 7/2016
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-016-0666-1

Other articles of this Issue 7/2016

Current Hypertension Reports 7/2016 Go to the issue

Therapeutic Trials (M Weir, Section Editor)

New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Obesity-Induced Hypertension: Brain Signaling Pathways

Device-Based Approaches for Hypertension (M Schlaich, Section Editor)

Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies

Hypertension and Emergency Medicine (T Rainer, Section Editor)

Asking the Patient or Measuring Blood Pressure in the Emergency Department: Which One is Best?

Resistant Hypertension (E Pimenta, Section Editor)

Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

A Systematic Review of Beliefs About Hypertension and its Treatment Among African Americans

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits